sur Laxxon Medical
Laxxon Medical to Present SPID® Technology at CPHI Milan 2024
Laxxon Medical, a pharmaceutical technology company from the US, is set to attend the CPHI Global event in Milan, Italy, from October 8-10, 2024. The company will showcase its cGMP printing technology at Adare Pharma Solution's facility in Pessano. This event gathers the global pharmaceutical community to explore new advancements in drug manufacturing.
The company, alongside Adare Pharma Solutions, is offering private tours of its new cGMP production unit. Laxxon's SPID® Technology, a screen printing process, facilitates the creation of complex oral dosage forms. It allows for the transition from clinical trials to mass production, optimizing drug release profiles.
This technology was licensed from Exentis Group, based near Zurich, granting Laxxon exclusive rights for pharmaceutical applications. Laxxon leverages the FDA's 505b(2) pathway in the US and the Hybrid applications in Europe for expedited market access.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Laxxon Medical